Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: a Small-scale Public Health Intervention Study

Launched by PETER STEINMANN · Nov 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called arpraziquantel (arPZQ) to help control schistosomiasis, a disease caused by parasites that can affect young children. The study is taking place in Côte d'Ivoire, Kenya, and Uganda, where researchers want to see how well different methods work for giving this child-friendly medicine to preschool-aged children, specifically those between 2 and 5 years old. The goal is to make sure these children, who often miss out on treatment, can receive arPZQ easily and safely.

To be eligible for the study, children must live in the area for at least six months, be between 24 and 59 months old, and have permission from their caregivers. They should not have serious health issues or be allergic to the medicine. During the trial, caregivers can expect their children to receive the treatment under close observation, and researchers will monitor how well the different delivery methods work. This is an important step towards improving health programs and making sure that more children receive the care they need to combat schistosomiasis effectively.

Gender

ALL

Eligibility criteria

• • Living in the designated implementation area since at least 6 months
• • Aged between 24 - 59 months
• • Informed consent available
• • No acute or chronic illness and/or inability to take oral medication
• • No reported history of seizures
• • No known allergic response to praziquantel